{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T04:33:45Z","timestamp":1649133225212},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,3,14]],"date-time":"2014-03-14T00:00:00Z","timestamp":1394755200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s13730-014-0115-4","type":"journal-article","created":{"date-parts":[[2014,3,13]],"date-time":"2014-03-13T07:37:16Z","timestamp":1394696236000},"page":"188-194","source":"Crossref","is-referenced-by-count":1,"title":["Acquired Fanconi syndrome due to long-term adefovir administration in a patient with IgG-kappa monoclonal gammopathy and kappa Bence-Jones protein"],"prefix":"10.1007","volume":"3","author":[{"given":"Shuzo","family":"Kaneko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,14]]},"reference":[{"key":"115_CR1","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1001\/jama.282.24.2305","volume":"282","author":"J Kahn","year":"1999","unstructured":"Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA. 1999;282:2305\u201312.","journal-title":"JAMA"},{"key":"115_CR2","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1523-1755.2004.00866.x","volume":"66","author":"H Izzedine","year":"2004","unstructured":"Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int. 2004;66:1153\u20138.","journal-title":"Kidney Int"},{"key":"115_CR3","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","volume":"131","author":"SJ Hadziyannis","year":"2006","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5\u00a0years. Gastroenterology. 2006;131:1743\u201351.","journal-title":"Gastroenterology"},{"key":"115_CR4","doi-asserted-by":"crossref","unstructured":"Tanaka M, Suzuki F, Sezaki H et al (2013) Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis. B J Gastroenterol. (Epub ahead of print).","DOI":"10.1007\/s00535-013-0779-0"},{"key":"115_CR5","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1124\/mol.56.3.570","volume":"56","author":"T Cihlar","year":"1999","unstructured":"Cihlar T, Lin DC, Pritchard JB, et al. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates human and rat renal organic anion transporter 1. Mol Pharmacol. 1999;56:570\u201380.","journal-title":"Mol Pharmacol"},{"key":"115_CR6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1081\/NCN-100002341","volume":"20","author":"T Cihlar","year":"2001","unstructured":"Cihlar T, Ho ES, Lin DC, et al. Human renal organic anion transporter (hOAT1) and its role in nephro- toxicity of antiviral nucleoside analogs. Nucleos Nucleot Nucleic Acids. 2001;20:641\u20138.","journal-title":"Nucleos Nucleot Nucleic Acids"},{"key":"115_CR7","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1124\/mol.106.028233","volume":"71","author":"T Imaoka","year":"2007","unstructured":"Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Functional involvement of multidrug resistance-associated protein 4 (MRP4\/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007;71:619\u201327.","journal-title":"Mol Pharmacol"},{"key":"115_CR8","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0168-8278(10)60016-5","volume":"52","author":"M Vigano","year":"2010","unstructured":"Vigano M, Lampertico P, Dongiovanni P, et al. A drug transporter gene polymorphism predicts renal tubular toxicity in patients with chronic hepatitis B on long-term adefovir and lamivudine combination. J Hepatol. 2010;52:S7.","journal-title":"J Hepatol"},{"key":"115_CR9","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/0006-2952(94)90600-9","volume":"48","author":"JM Cherrington","year":"1994","unstructured":"Cherrington JM, Allen SJ, McKee BH, Chen MS. Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine, ddCTP, AZTTP, and FIAUTP with human DNA polymerases beta and gamma. Biochem Pharmacol. 1994;48:1986\u20138.","journal-title":"Biochem Pharmacol"},{"key":"115_CR10","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1097\/00002030-199814000-00004","volume":"12","author":"K Brinkman","year":"1998","unstructured":"Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998;12:1735\u201344.","journal-title":"AIDS"},{"key":"115_CR11","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/hupa.2001.25586","volume":"32","author":"N Tanji","year":"2001","unstructured":"Tanji N, Tanji K, Kambham N, Markowitz GS, Bell A, D\u2019agati VD. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol. 2001;32:734\u201340.","journal-title":"Hum Pathol"},{"key":"115_CR12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2957\/kanzo.54.187","volume":"54","author":"E Eri Kumade","year":"2013","unstructured":"Eri Kumade E, Furusyo N, Mitsumoto F, et al. A case of Fanconi\u2019s syndrome caused by long-term administration of adefovir by a patient with chronic hepatitis B. Kanzo. 2013;54:187\u201393 (in Japanese).","journal-title":"Kanzo"},{"key":"115_CR13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00005792-200005000-00002","volume":"79","author":"T Messiaen","year":"2000","unstructured":"Messiaen T, Deret S, Mougenot B, et al. Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. Medicine. 2000;79:135\u201354.","journal-title":"Medicine"},{"key":"115_CR14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2169\/internalmedicine.46.1882","volume":"46","author":"T Hashimoto","year":"2007","unstructured":"Hashimoto T, Arakawa K, Ohta Y, et al. Acquired fanconi syndrome with osteomalacia secondary to monoclonal gammopathy of undetermined significance. Intern Med. 2007;46:241\u20135.","journal-title":"Intern Med"},{"key":"115_CR15","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1053\/j.ajkd.2009.08.010","volume":"55","author":"MR Elliott","year":"2010","unstructured":"Elliott MR, Cortese C, Moreno-Aspitia A, Dwyer JP. Plasma cell dyscrasia causing light chain tubulopathy without Fanconi syndrome. Am J Kidney Dis. 2010;55:1136\u201341.","journal-title":"Am J Kidney Dis"},{"key":"115_CR16","first-page":"338","volume":"10","author":"M Raja La","year":"2012","unstructured":"La Raja M, Barcobello M, Bet N, et al. Incidental finding of monoclonal gammopathy in blood donors: a follow-up study. Blood Transfus. 2012;10:338\u201343.","journal-title":"Blood Transfus"},{"key":"115_CR17","first-page":"265","volume":"33","author":"SL Strobel","year":"2003","unstructured":"Strobel SL. Transient paraproteinemia: an intriguing immunological anomaly. Ann Clin Lab Sci. 2003;33:265\u201370.","journal-title":"Ann Clin Lab Sci"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-014-0115-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13730-014-0115-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-014-0115-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T12:08:11Z","timestamp":1565266091000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13730-014-0115-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,14]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["115"],"URL":"https:\/\/doi.org\/10.1007\/s13730-014-0115-4","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,14]]}}}